<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131065</url>
  </required_header>
  <id_info>
    <org_study_id>IG0907</org_study_id>
    <nct_id>NCT01131065</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients</brief_title>
  <official_title>Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the efficacy, safety, and tolerability of
      Niuliva (Hepatitis B virus immune globulin) in the prophylaxis of hepatitis B virus (HBV)
      reinfection in patients submitted to liver transplantation due to HBV-induced liver disease
      by reaching and maintaining certain hepatitis B antibody (HBsAg) levels considered as
      protective during the first six and twelve months post-transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>HBV Recurrence</measure>
    <time_frame>First six and twelve months after liver transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>HBV recurrence is measured by seroconversion or reappearance of HBsAg and HBV DNA positivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)</measure>
    <time_frame>Days 3 to 7, Weeks 2 to 4, Months 2 to 6, and Months 7 to 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerance</measure>
    <time_frame>During and after each product administration (during the 12 month treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerance to the product administration will be measured by the detection of adverse events or clinically relevant changes in vital signs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Hepatitis B immune globulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group (newly liver transplanted subjects due to HBV induced liver disease)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepatitis B immune globulin</intervention_name>
    <description>Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
    <arm_group_label>Hepatitis B immune globulin</arm_group_label>
    <other_name>Niuliva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female.

          -  Patients from 18 to 70 years of age (both included).

          -  Serum HBV DNA-negative determined by DNA PCR-amplification assay just prior to
             anhepatic phase visit.

          -  Serum HBeAg negative just prior to anhepatic phase visit.

          -  Patients who are to undergo liver transplantation due to liver disease associated to
             HBV.

          -  The patient agrees to participate and comply with all the aspects of the protocol,
             including blood sampling, for the total duration of the study.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients who have already experienced a liver transplantation even for reasons not
             related to HBV infection.

          -  Patients with unknown serum HBV replication status (data on HBeAg and HBV DNA).

          -  Patients with known allergies to any component of Niuliva®.

          -  History of serious adverse events (SAEs) or frequent adverse events (AEs) related to
             the administration of human blood-derived products.

          -  Patient with unknown viral status for HCV, HAV, HIV type 1 and type 2

          -  Patients with selective IgA deficiency.

          -  Any haemostatic abnormality contraindicating i.v. injection according to the
             investigator's judgment.

          -  Patient suffers from any acute or chronic medical, surgical or psychiatric condition
             or laboratory abnormality that may increase the risk associated with the study
             participation or investigational product administration, or may interfere with the
             interpretation of the study results.

          -  Known abuse of alcohol, drugs or other chemical substances; or has done so in the
             past 6 months.

          -  Breast-feeding women or pregnant women at the time of inclusion or who are expecting
             to be pregnant within the next 7 months after inclusion.

          -  Subject has participated in any other investigational study within the last 3 months.

          -  Existing possibility that the patient may be treated with other products containing
             specific anti-hepatitis B immunoglobins (other than Niuliva®) in a period of 13
             months.

          -  Subject is incapable of giving consent personally.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>A.O.U. Policlinico Università di Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera S.Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 23, 2016</lastchanged_date>
  <firstreceived_date>May 25, 2010</firstreceived_date>
  <firstreceived_results_date>December 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Orthotopic liver transplantation</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Reinfection</keyword>
  <keyword>Protective titers</keyword>
  <keyword>HBsAb</keyword>
  <keyword>Hepatitis B virus immune globulin</keyword>
  <keyword>Niuliva</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifteen subjects (newly liver transplanted due to HBV induced liver disease) were screened in the study, all received the study medication, and all completed the clinical study.
First subject enrolled - 26 July 2010 Last subject completed - 16 June 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hepatitis B Immune Globulin</title>
          <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hepatitis B Immune Globulin</title>
          <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>18 to 70 years of age (inclusive)</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Alcohol consumption - abstemious</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="170.33" spread="8.08"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.73" spread="12.05"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hepatitis history</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Has chronic HBV</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Has fulminant HBV</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HBV Recurrence</title>
        <description>HBV recurrence is measured by seroconversion or reappearance of HBsAg and HBV DNA positivity</description>
        <time_frame>First six and twelve months after liver transplantation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hepatitis B Immune Globulin</title>
            <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HBV Recurrence</title>
            <description>HBV recurrence is measured by seroconversion or reappearance of HBsAg and HBV DNA positivity</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Six Months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Twelve Months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)</title>
        <time_frame>Days 3 to 7, Weeks 2 to 4, Months 2 to 6, and Months 7 to 12</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hepatitis B Immune Globulin</title>
            <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)</title>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="764.7" spread="375.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="910.7" spread="282.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="969.6" spread="96.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1000.0" spread="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1000.0" spread="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1073.6" spread="244.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="945.2" spread="250.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1029.2" spread="175.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="592.5" spread="260.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="439.2" spread="218.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="398.1" spread="272.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="351.9" spread="179.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="369.0" spread="182.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="277.7" spread="89.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="304.3" spread="50.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="266.0" spread="34.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="301.0" spread="61.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 11</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="273.3" spread="117.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="284.3" spread="137.47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerance</title>
        <description>Safety and tolerance to the product administration will be measured by the detection of adverse events or clinically relevant changes in vital signs.</description>
        <time_frame>During and after each product administration (during the 12 month treatment period)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hepatitis B Immune Globulin</title>
            <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety and Tolerance</title>
            <description>Safety and tolerance to the product administration will be measured by the detection of adverse events or clinically relevant changes in vital signs.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected up to 12 month following orthotopic liver transplant.</time_frame>
      <desc>The duration of treatment was 6 months after which subjects were offered the option to be treated for an additional 6 months (12 months total).</desc>
      <group_list>
        <group group_id="E1">
          <title>Hepatitis B Immune Globulin</title>
          <description>Treatment group
Hepatitis B immune globulin: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Liver transplant rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function tests abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhagic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Localized intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Biliary fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Kell blood group positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngeal culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokinesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site may publish results from the Study, after providing Sponsor thirty days’ notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsor’s request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsor’s request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor’s Inventions.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Woodward, BSc, M.Sc</name_or_title>
      <organization>Instituto Grifols, S.A.</organization>
      <phone>+34 935712200</phone>
      <email>michael.woodward@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
